Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting Insulin

NCT06592950 | Completed

• 2 other identifiers: DAS-7791U1111-1293-3919
• Study Type: observational
• Target: 513
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this research is to assess T2DM patient preferences for a once weekly insulin treatment. The study involves a qualitative interview phase and quantitative survey phase with a Discrete Choice Experiment (DCE).

Conditions

Type-2 Diabetes Mellitus (T2DM)

Outcome Measures

Primary Outcomes (1)

• T2DM patient preferences for a once weekly insulin treatment

  Pre-defined open-ended questions and Discrete Choice Experiment online survey

  Day of interview/survey completion (Day 1)

Study Arms (2)

Quantitative online survey

Across four markets (Canada, France, Spain and Japan)

Other: No treatment given

Qualitative interviews

Conducted in Canada

Other: No treatment given

Interventions

No treatment given OTHER

Online survey

Quantitative online survey

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Type-2 diabetes mellitus (T2DM) patients

You may qualify if:

• Patient is an adult aged 18 years or over
• Patient was diagnosed with type-2 diabetes mellitus (T2DM) greater than or equal to 180 days prior to the day of screening
• Patient is currently prescribed a diabetes treatment (e.g., Metformin/Sus, DPP4i, SGLT2i, GLP-1 RA and/or basal insulin)
• Patient is willing and able to provide written informed consent to participate
• For qualitative interviews:
• Patient is a fluent speaker of English and is able to read, write, and fully understand the English language
• Patient is a resident in Canada
• For quantitative online survey:
• Patient is a fluent speaker of the local language (English/French/Spanish or Japanese) and is able to read, write and fully understand the local language
• Patient is a resident of either Canada, France, Spain or Japan

You may not qualify if:

• Patient is currently employing a basal-bolus insulin treatment regimen to manage their diabetes
• Patient is unwilling or unable to comply with the needs of the study or has a physical, behavioural or mental condition that, in the opinion of the recruiter may affect the patient's ability to take part in the study, understand the nature, scope and possible consequences of the study, or the responses they might provide.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

Novo Nordisk

Søborg, 2860, Denmark

Location

Study Officials

• Clinical Transparency dept. 2834

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 9, 2024
• First Posted: September 19, 2024
• Study Start: November 2, 2023
• Primary Completion: April 29, 2024
• Study Completion: April 29, 2024
• Last Updated: September 19, 2024

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will share

Locations

DK (1)